Abstract
0119 Montelukast (ML), a leukotriene receptor antagonist, attenuates exercise-induced bronchoconstriction (EIB) and its symptoms; however, little is known regarding the acute influence of ML on exercise performance. PURPOSE: To examine the effects of ML on physical performance in EIB- and EIB+ athletes. METHODS: Thirty athletes (27 male, 3 female) performed a 6-min time trial in sub-freezing conditions (−2.5 ± 0.4°C) using an electronically braked cycle ergometer to obtain total work accumulated (kJ). Subjects performed the exercise challenge twice (6–8 hours after either ML or placebo) and were evaluated for EIB following each exercise trial. RESULTS: No significant differences were found in work accumulated between placebo and treatment trials for pooled subjects (90.5 ± 18.6 and 91.7 ± 15.6 kJ, respectively) or subjects grouped according to EIB status (93.5 ± 19.7 and 95.2 ± 14.8 kJ for EIB- subjects, respectively; 83.3 ± 14.3 and 83.6 ± 14.9 kJ for EIB+ subjects, respectively). CONCLUSIONS: A single dose of ML had no ergogenic effect for EIB- and EIB+ subjects performing short-duration high intensity exercise in sub-freezing conditions. Supported by Merck and Co., Inc. grant #SING-US-63-01
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call